Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 12 | 2024 | 2665 | 1.440 |
Why?
|
| Spinal Neoplasms | 6 | 2024 | 670 | 1.160 |
Why?
|
| Pelvic Bones | 2 | 2024 | 102 | 1.050 |
Why?
|
| Bone Cements | 1 | 2024 | 50 | 0.920 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2024 | 53 | 0.890 |
Why?
|
| Denosumab | 1 | 2024 | 72 | 0.880 |
Why?
|
| Femur | 4 | 2023 | 161 | 0.680 |
Why?
|
| Sarcoma | 8 | 2024 | 1839 | 0.610 |
Why?
|
| Glomus Tumor | 1 | 2017 | 29 | 0.560 |
Why?
|
| Sciatic Nerve | 1 | 2017 | 120 | 0.550 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2017 | 72 | 0.540 |
Why?
|
| Neoadjuvant Therapy | 3 | 2024 | 5231 | 0.450 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2012 | 20 | 0.410 |
Why?
|
| Chondroma | 1 | 2012 | 30 | 0.410 |
Why?
|
| Femoracetabular Impingement | 1 | 2011 | 4 | 0.380 |
Why?
|
| Prosthesis Implantation | 3 | 2021 | 242 | 0.380 |
Why?
|
| Arthroplasty | 1 | 2011 | 23 | 0.380 |
Why?
|
| Acetabulum | 1 | 2011 | 41 | 0.370 |
Why?
|
| Thoracic Vertebrae | 2 | 2024 | 200 | 0.370 |
Why?
|
| Spinal Cord Compression | 3 | 2024 | 167 | 0.370 |
Why?
|
| Osteotomy | 2 | 2011 | 105 | 0.360 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2024 | 293 | 0.340 |
Why?
|
| Chondrosarcoma | 2 | 2023 | 213 | 0.340 |
Why?
|
| Surgical Oncology | 2 | 2023 | 211 | 0.330 |
Why?
|
| Liposarcoma | 2 | 2024 | 248 | 0.320 |
Why?
|
| Femoral Neoplasms | 4 | 2016 | 66 | 0.320 |
Why?
|
| Osteolysis | 3 | 2024 | 99 | 0.320 |
Why?
|
| Limb Salvage | 2 | 2021 | 162 | 0.290 |
Why?
|
| Free Tissue Flaps | 2 | 2021 | 374 | 0.260 |
Why?
|
| Prostheses and Implants | 2 | 2021 | 294 | 0.260 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2023 | 927 | 0.250 |
Why?
|
| Tibia | 2 | 2016 | 125 | 0.250 |
Why?
|
| Fracture Fixation, Intramedullary | 2 | 2016 | 41 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2019 | 10400 | 0.250 |
Why?
|
| Fractures, Spontaneous | 2 | 2016 | 87 | 0.250 |
Why?
|
| Femoral Fractures | 2 | 2016 | 66 | 0.240 |
Why?
|
| Cementation | 1 | 2024 | 10 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 7895 | 0.230 |
Why?
|
| Osteocytes | 1 | 2024 | 35 | 0.230 |
Why?
|
| Gap Junctions | 1 | 2024 | 48 | 0.230 |
Why?
|
| Diaphyses | 1 | 2023 | 11 | 0.220 |
Why?
|
| Fibula | 2 | 2021 | 153 | 0.210 |
Why?
|
| Pelvic Neoplasms | 1 | 2024 | 199 | 0.200 |
Why?
|
| Bone and Bones | 3 | 2023 | 605 | 0.200 |
Why?
|
| Bone Density Conservation Agents | 1 | 2024 | 205 | 0.200 |
Why?
|
| Humerus | 2 | 2023 | 53 | 0.190 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2024 | 296 | 0.190 |
Why?
|
| Osteoblastoma | 1 | 2020 | 15 | 0.180 |
Why?
|
| Osteoma, Osteoid | 1 | 2020 | 24 | 0.180 |
Why?
|
| Osteonecrosis | 1 | 2021 | 56 | 0.180 |
Why?
|
| Male | 21 | 2024 | 128315 | 0.180 |
Why?
|
| Sarcoma, Ewing | 1 | 2024 | 428 | 0.180 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 38 | 0.180 |
Why?
|
| SEER Program | 1 | 2024 | 1047 | 0.180 |
Why?
|
| Humans | 37 | 2024 | 270740 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 96 | 0.170 |
Why?
|
| Treatment Outcome | 13 | 2024 | 33737 | 0.170 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2019 | 17 | 0.170 |
Why?
|
| Orthopedic Procedures | 2 | 2019 | 145 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2024 | 2386 | 0.160 |
Why?
|
| Frozen Sections | 1 | 2019 | 113 | 0.160 |
Why?
|
| Lumbar Vertebrae | 1 | 2020 | 247 | 0.160 |
Why?
|
| Kidney Neoplasms | 3 | 2024 | 3108 | 0.160 |
Why?
|
| Lower Extremity | 1 | 2021 | 280 | 0.160 |
Why?
|
| Hemangioma | 1 | 2020 | 157 | 0.150 |
Why?
|
| Prosthesis-Related Infections | 1 | 2021 | 230 | 0.150 |
Why?
|
| Drainage | 1 | 2021 | 462 | 0.150 |
Why?
|
| Plasmacytoma | 1 | 2019 | 125 | 0.150 |
Why?
|
| Bone Diseases | 1 | 2019 | 143 | 0.150 |
Why?
|
| Adolescent | 11 | 2024 | 32767 | 0.150 |
Why?
|
| Female | 21 | 2024 | 148940 | 0.150 |
Why?
|
| Radiography | 5 | 2020 | 1986 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 2 | 2024 | 1109 | 0.140 |
Why?
|
| Epidural Space | 1 | 2016 | 47 | 0.140 |
Why?
|
| Quality of Life | 2 | 2024 | 4761 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 477 | 0.130 |
Why?
|
| Patella | 1 | 2016 | 39 | 0.130 |
Why?
|
| Leg Length Inequality | 1 | 2015 | 12 | 0.130 |
Why?
|
| Postoperative Complications | 4 | 2021 | 5681 | 0.130 |
Why?
|
| Decompression, Surgical | 1 | 2016 | 144 | 0.130 |
Why?
|
| Adult | 15 | 2024 | 82040 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 533 | 0.130 |
Why?
|
| Osteosarcoma | 2 | 2020 | 950 | 0.130 |
Why?
|
| Middle Aged | 16 | 2024 | 90352 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2019 | 728 | 0.120 |
Why?
|
| Osteoblasts | 1 | 2017 | 393 | 0.120 |
Why?
|
| Femur Neck | 1 | 2014 | 21 | 0.120 |
Why?
|
| Spine | 1 | 2016 | 312 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2022 | 1471 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 605 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2019 | 345 | 0.110 |
Why?
|
| Aged | 15 | 2024 | 73333 | 0.110 |
Why?
|
| Aged, 80 and over | 9 | 2023 | 30998 | 0.110 |
Why?
|
| Cadaver | 2 | 2011 | 202 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 495 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.100 |
Why?
|
| Total Disc Replacement | 1 | 2012 | 3 | 0.100 |
Why?
|
| Young Adult | 9 | 2024 | 22251 | 0.100 |
Why?
|
| Search Engine | 1 | 2012 | 17 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.100 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2014 | 261 | 0.100 |
Why?
|
| Biopsy | 1 | 2019 | 3484 | 0.100 |
Why?
|
| Retrospective Studies | 11 | 2023 | 39890 | 0.090 |
Why?
|
| Cervical Vertebrae | 1 | 2012 | 219 | 0.090 |
Why?
|
| Arthralgia | 1 | 2011 | 97 | 0.090 |
Why?
|
| Apoptosis | 1 | 2024 | 7757 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2019 | 1383 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1335 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2399 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 4831 | 0.080 |
Why?
|
| Linear Models | 1 | 2011 | 1093 | 0.080 |
Why?
|
| Internet | 1 | 2012 | 690 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 2328 | 0.070 |
Why?
|
| Reoperation | 2 | 2023 | 1392 | 0.070 |
Why?
|
| Child | 7 | 2024 | 30559 | 0.070 |
Why?
|
| Rotator Cuff | 1 | 2006 | 23 | 0.070 |
Why?
|
| Tendon Injuries | 1 | 2006 | 26 | 0.070 |
Why?
|
| Arthroscopy | 1 | 2006 | 42 | 0.070 |
Why?
|
| Orthopedics | 1 | 2006 | 80 | 0.060 |
Why?
|
| Shoulder Fractures | 1 | 2005 | 9 | 0.060 |
Why?
|
| Connexin 43 | 1 | 2024 | 46 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 145 | 0.050 |
Why?
|
| Extremities | 1 | 2023 | 311 | 0.050 |
Why?
|
| Sacrum | 1 | 2021 | 138 | 0.040 |
Why?
|
| Bone Transplantation | 1 | 2021 | 152 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2024 | 550 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 14012 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 15218 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 714 | 0.040 |
Why?
|
| Disease Progression | 2 | 2024 | 6867 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2023 | 522 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 251 | 0.040 |
Why?
|
| Operative Time | 1 | 2020 | 255 | 0.040 |
Why?
|
| Survival Rate | 2 | 2024 | 12541 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 657 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 255 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2020 | 295 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1060 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 1424 | 0.040 |
Why?
|
| Texas | 2 | 2020 | 6449 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2017 | 136 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 269 | 0.030 |
Why?
|
| Fracture Healing | 1 | 2016 | 42 | 0.030 |
Why?
|
| Risk | 1 | 2021 | 1939 | 0.030 |
Why?
|
| Infant | 2 | 2024 | 13999 | 0.030 |
Why?
|
| Prognosis | 3 | 2019 | 22505 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2019 | 9470 | 0.030 |
Why?
|
| Epiphyses | 1 | 2015 | 14 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 7783 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2016 | 107 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 14849 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2020 | 1016 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1379 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2024 | 17061 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 738 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 722 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2023 | 2062 | 0.030 |
Why?
|
| Vancomycin | 1 | 2016 | 292 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 2271 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 1823 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2020 | 1567 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 4963 | 0.030 |
Why?
|
| Pain Management | 1 | 2019 | 712 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 631 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 681 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1252 | 0.030 |
Why?
|
| Risk Factors | 2 | 2023 | 17888 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 2025 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 2835 | 0.030 |
Why?
|
| Marketing of Health Services | 1 | 2012 | 33 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 4048 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8699 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 3658 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1610 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2019 | 4019 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 5101 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 5162 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 5923 | 0.020 |
Why?
|
| Mice | 2 | 2024 | 35600 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6256 | 0.020 |
Why?
|
| Neoplasms | 1 | 2016 | 15927 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 3640 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 7655 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 9292 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 9039 | 0.020 |
Why?
|
| Pain | 1 | 2016 | 1694 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 10265 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 6764 | 0.020 |
Why?
|
| United States | 1 | 2024 | 15861 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2017 | 4116 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 61956 | 0.020 |
Why?
|
| Rotator Cuff Injuries | 1 | 2006 | 24 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 5824 | 0.020 |
Why?
|
| Shoulder Dislocation | 1 | 2005 | 12 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 7238 | 0.020 |
Why?
|
| Rotation | 1 | 2005 | 97 | 0.020 |
Why?
|
| Shoulder Joint | 1 | 2005 | 63 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 7381 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 3187 | 0.010 |
Why?
|
| Mutation | 1 | 2023 | 15912 | 0.010 |
Why?
|
| Observer Variation | 1 | 2005 | 709 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 4492 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 6177 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 12033 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 13414 | 0.010 |
Why?
|